galantamine has been researched along with rasagiline in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Antonov, L; Atanasov, AG; Balacheva, AA; Faraone, I; Gastreich, M; Georgieva, MG; Hristova, S; Milella, L; Russo, D; Stammler, HG; Tzvetkov, NT | 1 |
| Amoroso, R; Carradori, S; De Filippis, B; Fantacuzzi, M | 1 |
2 review(s) available for galantamine and rasagiline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Resveratrol-based compounds and neurodegeneration: Recent insight in multitarget therapy.
Topics: Humans; Neurodegenerative Diseases; Polyphenols; Resveratrol; Stilbenes; Structure-Activity Relationship | 2022 |
1 other study(ies) available for galantamine and rasagiline
| Article | Year |
|---|---|
Carboxamides vs. methanimines: Crystal structures, binding interactions, photophysical studies, and biological evaluation of (indazole-5-yl)methanimines as monoamine oxidase B and acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Amides; Cell Proliferation; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; Imines; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |